

## **Medical Preferred Drug List**

Step Therapy (Applies to the Outpatient setting only.)

The CareFirst BlueCross BlueShield Community Health Plan Maryland Medical Preferred Drug List (PDL) encourages utilization of clinically appropriate and lower net cost products within the following drug and therapeutic drug classes available under the The CareFirst BlueCross BlueShield Community Health Plan Maryland medical benefit.

The listed preferred products must be used first and do not require a prior authorization. A prior authorization process is in place for specific circumstances that may warrant a need for a non-preferred product. The CareFirst BlueCross BlueShield Community Health Plan Maryland members who are actively receiving treatment will be allowed to continue with a non-preferred product on the The CareFirst BlueCross BlueShield Community Health Plan Maryland Medical PDL as long as their current medical records support its use.

Drug Class	Preferred Product(s)	Non-Preferred Product(s)
Acromegaly	Somatuline Depot	Sandostatin LAR Signifor LAR Somavert
Botulinum Toxins	Dysport	Botox Myobloc Xeomin
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Zarxio	Granix Leukine Neupogen Nivestym
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Ziextenzo	Fulphila Neulasta syringe Nyvepria Udenyca
Hereditary Angioedema	Berinert	Ruconest
Lysosomal Storage Disorders – Gaucher Disease	Cerezyme	Elelyso VPRIV
Multiple Sclerosis (Infused)	Ocrevus Tysabri	Lemtrada



## Prior Authorization\* (Applies to the Outpatient setting only.)

The following drugs continue to require prior authorization:

- Darzalex
- Herceptin
- Keytruda
- Opdivo

CareFirst BlueCross BlueShield Community Health Plan Maryland is the business name of CareFirst Community Partners, Inc. an independent licensee of the Blue Cross and Blue Shield Association. BLUE CROSS<sup>®</sup>, BLUE SHIELD<sup>®</sup> and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.

<sup>\*</sup>Prior authorization was effective on medical claims with dates of service January 1, 2021.